#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Dedifferentiated liposarcoma Palmar-plantar erythrodysaesthesia syndrome Transitional cell cancer of the renal pelvis and ureter Andersen-Tawil syndrome Acquired ATTR amyloidosis Parkinson's disease Carcinoid syndrome Cortical dysplasia Synovial sarcoma Central nervous system neoplasm Orthostatic hypotension C3 glomerulopathy Muscular dystrophy Epilepsy Langerhans cell sarcoma More trials…

    Learn about Rare Diseases

    Chronic granulomatous disease – Diagnostics Angelman’s syndrome – Diagnostics Pleomorphic leiomyosarcoma – Trials in Disease Haemophilia A without inhibitors – Trials in Disease Angiosarcoma – Trials in Disease Indolent systemic mastocytosis – Trials in Disease Hereditary hypophosphataemic rickets – Treatment SAPHO syndrome – Diagnostics Burkitt’s lymphoma – Life with Disease Amyotrophic lateral sclerosis – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Cetrorelix Carcik-Cd19 Cells Daratumumab Vortioxetine Neridronate Sodium Exagamglogene Autotemcel Alendronic Acid C1 Esterase Inhibitor (Human) Durvalumab Indometacin Ph. Eur. Skin Autograft Navitoclax Specific Nucleic Acid Sna-Ebv Elivaldogene Autotemcel Atorvastatin Opelconazole Buparlisib Efanesoctocog Alfa Sulfamethizole Vinblastine Sulfate More therapies…

    Learn about Your Condition

    BRAF gene mutation Upper limb fracture Nephrotic syndrome Deafness bilateral Meniscus operation Chordoma Lichenoid keratosis Polycystic liver disease Iron deficiency Genitourinary tract neoplasm Sickle cell anaemia Tympanic membrane hyperaemia Small intestine leiomyosarcoma Infantile apnoea Primary biliary cholangitis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Vaccine

  • Study on the Effectiveness and Safety of Regorafenib for Patients with Metastatic Bone Sarcomas

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Chondrosarcoma metastatic
    • Chordoma
    • Osteosarcoma metastatic
    Investigated Drugs:
    • Regorafenib
    France

  • Study on Reduced Intensity Radio-Chemotherapy for Stage IIA/B Seminoma Using Etoposide, Cisplatin, and Carboplatin for Patients with Stage IIA/B Seminoma

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Etoposide
    Germany

  • Study of Radotinib safety and effectiveness compared to placebo in people with Parkinson’s disease

    Not recruiting

    2 1
    Investigated Drugs:
    • Radotinib Dihydrochloride
    France

  • Study on the Effectiveness and Safety of Rozanolixizumab for Adults with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOG-AD)

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Rozanolixizumab
    Belgium Czechia France Germany Greece Italy +4

  • Study Comparing Teclistamab, Talquetamab, and Drug Combination for Patients with Newly Diagnosed Multiple Myeloma Not Suitable for Stem Cell Transplant

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Dexamethasone Ph. Eur.
    • Talquetamab
    • Daratumumab
    Austria Belgium Czechia Denmark France Germany +8

  • Study of petosemtamab with pembrolizumab compared to pembrolizumab alone in patients with head and neck cancer who have not received previous treatment for advanced disease

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Pembrolizumab
    • Petosemtamab
    Austria Belgium Croatia Czechia France Germany +8
Previous Page
1 … 1,635 1,636 1,637 1,638 1,639 … 1,645
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!